Rafael Fonseca, Chief Innovation Officer and Professor of Medicine at Mayo Clinic, shared a post on X:
“Classifying myeloma treatments as curative versus control ones – the time is now!”
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared this post, adding:
“Brilliant summary of Bruno Paiva research into MRD myeloma. (Although I’d wager that MRD-neg ≥VGPR at an early timepoint as MRD-neg CR).
Eloquently worded by Rafael Fonseca: I’m excited for the day that CR vs VGPR vs PR is relegated to a legacy academic exercise alone!”
More posts featuring Rafael Fonseca and Rahul Banerjee.